Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Taichi Minami, Akiko Kameda & Yasuo Terauchi. (2021) An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2087-2094.
Read now
Read now
Articles from other publishers (4)
Saad U Rehman & Faiqa Rahman. (2020) Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus.
Crossref
Crossref
Kyu Hang LeeSang Don LeeNamdu KimKwee Hyun SuhYoung Hoon KimSang Soo Sim. (2019)
Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor,
in vitro
and
in vivo
. The Korean Journal of Physiology & Pharmacology 23:1, pages 55.
Crossref
Crossref
Atsushi Tanaka & Koichi Node. (2017) Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, Chie Aoki, Masaaki Sagara, Kazunori Yanagi, Kunihiro Suzuki & Yoshimasa Aso. (2017) Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy 8:4, pages 821-827.
Crossref
Crossref